Calypso Biotech is a biotechnology company that developes therapeutics for autoimmune diseases.
Calypso Biotech has raised $9.5M in total funding. The most recent round was Series A. The last funding was announced in September 2021.
Calypso Biotech's investors include Fountain Healthcare Partners, Johnson & Johnson Innovation, Inkef, Gilde Healthcare, M Ventures.
Calypso Biotech is headquartered in Plan-les-ouates, Switzerland.
Calypso Biotech is a biotechnology company that developes therapeutics for autoimmune diseases.
Calypso Biotech is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Calypso Biotech — Funding & Investors." VCBacked, September 9, 2021, https://www.vcbacked.co/company/calypso-biotech. Accessed August 13, 2026.
VCBacked. (2021). Calypso Biotech — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/calypso-biotech
{{cite web |title=Calypso Biotech — Funding & Investors |url=https://www.vcbacked.co/company/calypso-biotech |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated